Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - CNS tumours

3919 - Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: a randomised, open-label trial

Date

19 Oct 2018

Session

Proffered Paper session - CNS tumours

Presenters

Emilie Le Rhun

Citation

Annals of Oncology (2018) 29 (suppl_8): viii122-viii132. 10.1093/annonc/mdy273

Authors

E. Le Rhun1, A. Mailliez1, J. Wallet2, I. Rodrigues1, T. Boulanger3, I. Desmoulins4, J. Barriere5, M. Fabbro6, S. Taillibert7, C. Andre8, M.C. Le Deley2, M. Weller9, J.M. Bonneterre10

Author affiliations

  • 1 Breast Cancer Unit, Oscar Lambret Center, 59000 - Lille/FR
  • 2 Department Of Biostatistics, Oscar Lambret Center, 59000 - Lille/FR
  • 3 Department Of Radiology, Oscar Lambret Center, 59000 - Lille/FR
  • 4 Department Of Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 5 Department Of Medical Oncology, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 6 Department Of Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 7 Neuro-oncology, Pitié-Salpétrière Hospital, 75000 - Paris/FR
  • 8 Department Of Pathology, Oscar Lambret Center, 59000 - Lille/FR
  • 9 Neurology, University Hospital and University of Zurich, Zurich/CH
  • 10 Breast Cancer Unit, Centre Oscar Lambret, 59020 - Lille/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3919

Background

The role of intra-cerebrospinal fluid (CSF) therapy for the treatment of leptomeningeal metastasis (LM) remains controversial.

Methods

We conducted a multicenter randomized open-label study to explore the effect of the addition of liposomal cytarabine to systemic therapy for the treatment of LM from breast cancer. Inclusion was based on the detection of tumor cells in the CSF or typical clinical and magnetic resonance imaging (MRI) signs of LM. Patients were randomly assigned to receive systemic therapy alone (arm A) or systemic therapy plus intra-CSF liposomal cytarabine (5 injections of 50 mg x 2 weeks, followed by monthly injections of 50 mg until progression, unacceptable toxicity or for 1 year) (arm B). Neurological and quality of life evaluation was performed monthly, cerebrospinal MRI every 2 months. The primary endpoint was progression-free survival in the leptomeningeal compartment (LM-PFS); 66 were required to ensure 80% power for a hazard ratio of 0.5, and a two-sided alpha=5%. Overall survival (OS) was a secondary efficacy endpoint.

Results

Thirty-seven patients were assigned to arm A, 36 patients to arm B. Baseline characteristics were similar in both arms. The median number of liposomal cytarabine injections in arm B was 5 (range 1-20). Focal radiotherapy was performed in 6 (16%) and 5 (14%) patients in arms A and B, respectively. Serious adverse events were reported in 6 and 14 patients in arms A and B. In the intent-to-treat population, median LM-PFS as assessed by the local investigator was 2.0 months (95% confidence interval (CI) 1.3 – 2.7) in arm A versus 4.3 months (95% CI 2.3 – 5.7) in arm B (HR = 0.57, 95% CI 0.35 – 0.92, p = 0.02). Sixty-eight patients have died. Actuarial median OS was 4.0 months (95% CI 2.2-6.5) in arm A versus 7.3 months (95%CI 3.9-12.6) in arm B (HR = 0.80, 95% CI 0.50-1.29, p = 0.35). Centrally reviewed LM-PFS, patient-reported outcomes (quality of life, functional, emotional status) over time will also be reported.

Conclusions

The addition of liposomal cytarabine to systemic therapy may improve LM-related PFS but does not significantly improve survival. Quality of life data will be essential to determine a possible clinical benefit afforded by intrathecal chemotherapy.

Clinical trial identification

NCT01645839.

Legal entity responsible for the study

Oscar Lambret Center, Lille, France.

Funding

Mundipharma.

Editorial Acknowledgement

None

Disclosure

E. Le Rhun: Research funding: Mundipharma; Honoraria for lecture: Mundipharma. M. Weller: Honoraria for lecture: Mundipharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings